Hany Onsy Habashy

MBBCh, MSc, MD, PhD

Personal information and Contact Details

Date of Birth: 27/12/1973
Place of Birth: Egypt
Social Status: Married
Home Phone: (0020)502331986
Mobile Phone :(0020)1223912841, the current is (00965)50830383
E-mail: hanyonsy@mans.edu.eg, hanyonsy@yahoo.com

Qualifications

1-**Medical Degree MD, MBBCh.** Faculty of Medicine, Mansoura University, Mansoura, Egypt, November 1997 **(Excellent with honour).**
2-**Master's Degree, MSc Pathology**. Faculty of Medicine, Mansoura University, Mansoura, Egypt, May 2004. MSc thesis titled "An immunohistochemical study of p53 product and factor VIII in breast cancer and regional lymph nodes"
3-**Doctoral Degree, PhD Pathology.** Faculty of Medicine and Health Sciences, School of Molecular Medical Sciences, Division of Pathology, The University of Nottingham, Nottingham, UK (September 2006- March 2011). PhD thesis titled "The Biological Heterogeneity of Oestrogen Receptor Positive Breast Cancer and its Phenotypic Characterisation"

Employment

1-Rotating internship: for 12 Months at Mansoura University Hospitals from 3-1998 to 2-1999.
2-Demonstrator of Pathology from 30-5-1999 to 13-9-2004, Department of Histopathology, Faculty of Medicine, Mansoura University, Egypt.
3-Assistant lecturer of Pathology, Department of Pathology, Faculty of Medicine, Mansoura University, Egypt, from 14-9-2004 to 4-7-2011.
4-Lecturer of Pathology and Consultant Pathologist, Department of Pathology, Faculty of Medicine, Mansoura University, Egypt, from 5-7-2011 (to date, on leave to Kuwait).

Work and Research Experience

Involved in one of the diagnostic histopathology groups. Hence, responsible for examination of the gross specimens, selection and cutting of required sections and description of the gross and microscopic pictures. These groups make monthly rotation to achieve all fields of histopathology; Breast Pathology,Gastrointestinal Pathology, Hepatobiliary Pathology, Dermatopathology, Neuropathology, Orthopaedic Pathology, Head and Neck Pathology, Gynaecological Pathology, Pulmonary Pathology, Paediatrics Pathology, Cytology, and soft tissue Pathology. Involved in the teaching programs of General and Special Pathology for third year medical students, Mansoura University.

During my work and study in UK: Previous experience in Diagnostic Molecular Pathology techniques, DNA and RNA extraction, Tissue Microarray Construction, QPCR, Laser Capture Microdissection, Western Blotting and Immunohistochemistry.During my PhD studies, I had the opportunity to work with Prof Ian O Ellis who is considered to be one of the leading international experts of Breast Pathology and the inventor of the modified breast cancer grading system and The Nottingham Prognostic Index and The president of PathSoc of Great Britain and Ireland. I also had the chance to collaborate with other internationally recognised research groups within the UK in the Tenovus Centre for Cancer Research in Cardiff, Wales, UK (Prof Robert Nicholson and Dr Julia Gee), Cambridge Research Institute (Prof Carlos Caldas) and Nottingham Trent University (Prof Graham Ball). These successful collaborations have led to a number of novel peer reviewed publications in high profile international journals.

Teaching Experience

Involved in the teaching programs of General and Special Pathology for:
1-Third year medical students, Mansoura University.
2-Second year students, School of Dentistry, Mansoura University.
3-Fourth year students, School of Pharmacy, Mansoura University.
4-Pathology technical students, Mansoura University.

Main Research Fields and Collaboration

During my MD and PhD, I have concentrated mainly on breast cancer pathology with special emphasis on oestrogen receptor positive subtype trying to develop a novel subclassification of this important cancer group. My PhD project was a part of an ongoing program at the University of Nottingham investigating the biological and molecular genetic characteristics of human breast cancer aiming to improve classification and hence clinical management of this common disease. The project involved the analysis of a large tissue bank of formalin fixed and fresh frozen breast cancers (1902 cases) using laboratory molecular techniques including immunohistochemistry, gene expression array, and real-time PCR. Data was interrogated using conventional statistical analysis as well as bioinformatics methods including artificial neural network and clustering analysis.

Publications

1-Rakha EA, El-Sayed ME, Powe DG, Green AR, **Habashy H**, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO: Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. European Journal of Cancer, 2008, 44(1):73-83.

2-**Habashy HO**, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO:Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.European Journal of Cancer. 2008, 44(11):1541-51.

3-Rakha EA, Elsheikh SE, Aleskandarany MA, **Habashi HO**, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO:Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clinical Cancer Research. 2009, 15(7):2302-10.

4- **Habashy HO**, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM: Transferrin receptor (CD71) is a marker

of poor prognosis in breast cancer and can predict response to tamoxifen.Breast Cancer Research and Treatment. 2010, 119 (2):283-93.

5-**Habashy HO**, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR, Ellis IO: The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.Breast Cancer Research and Treatment. 2010, 120 (3):603-12.

6-**Habashy HO**, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO: RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.Breast Cancer Research and Treatment.2011 Jul;128(2):315-26

7-Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, **Habashy HO**, Green AR, Reis-Filho JS, Ellis IO: Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. Journal of Pathology. 2010, 222(4):388-99.

8- Powe DG, Voss MJ, Zänker KS, **Habashy HO**, Green AR, Ellis IO, Entschladen F: Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010, 1(7):628-38.

9-Powe DG, Voss MJ, **Habashy HO**, Zänker KS, Green AR, Ellis IO, Entschladen F: Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Research and Treatment. 2011 Nov;130(2):457-63

10- **Habashy HO**, Rakha EA, Ball G, Aleskandarany M, Ahmed M, Ellis IO, Green AR, Powe DG:FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Research and Treatment.2011 Aug;129(1):11-21

11**- Habashy HO**, Powe DG, Abdel-Fatah TM, Gee MWJ, Nicholson IR, Green AR, Rakha EA, Ellis IO; A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.Histopathology. 2012 May;60(6):854-63.

12-**Habashy HO**, Powe DG, Green AR, Rakha EA, Macmillan RD, Ellis IO: Coactivator-associated arginine methyltransferase-1(CARM1) expression in breast cancer: clinicopathological and prognostic significance. Breast Cancer Res Treat. 2013 Jul;140(2):307-16.

13-Tom Groot Kormelink1, Desmond G. Powe, Sylvia A. Kuijpers, Abulikemu Abudukelimu, Marcel H.A.M. Fens, Ebel H.E. Pieters, Willemiek W. Kassing-van der Ven, **Hany O. Habashy**, Ian O. Ellis, Bart R. Blokhuis1, Marco Thio, Wim E. Hennink, Gert Storm, Frank A. Redegeld, and Raymond M. Schiffelers: Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. Oncotarget. 2014 May 30;5(10):3159-67

14-Powe DG, Dhondalay GK, Lemetre C, Allen T**, Habashy HO**, Ellis IO, Rees R, Ball GR : DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.PLoS One. 2014 Jan 2;9(1):e84428.

15- Ahmed RA[1], Shebl AM[1], **Habashy HO**: Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study. Cancer Biol Med. 2017 Aug;14(3):319-326.

16-Sylvia A Ashamallah, Mie A Mohamed, **Hany Onsy Habashy**: Value of histopathological characteristics and protein expression of p57 and Ki67 inmolar pregnancy: In preparation

Selected Presented Abstracts at National and International Conferences

1-**Habashy HO**, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO: FOXA1 Expression in Breast Cancer and its Prognostic Significance. Has been presented as a poster presentation at the scientific meeting of the Pathological Society of Great Britain and Ireland, Leeds, 1-4 July 2008.

2**- Habashy HO**, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM: Transferrin Receptor (CD71) Expression in Breast Cancer and its Prognostic Significance. Has been presented as a poster presentation at the scientific meeting of the Pathological Society of Great Britain and Ireland, Leeds, 1-4 July 2008.

3-**Hany Onsy Habashy**, Desmond G Powe, Emad A Rakha, Claire Paish, Andrew R Green and Ian O Ellis: CARM1 Expression in Breast Cancer and Luminal-like/Oestrogen Receptor Positive Subtype: Clinicopathological and Prognostic Associations. Has been presented as a poster presentation at the scientific meeting of the Pathological Society of Great Britain and Ireland, Cardiff, 30 June-3 July 2009.

4-**Hany Onsy Habashy**, Desmond G Powe, Emad A Rakha, Claire Paish, Andrew R Green and Ian O Ellis: Luminal Breast Cancer: Identification of Significant Prognostic Patho-biological Indicators. Has been presented as a poster presentation at the scientific meeting of the Pathological Society of Great Britain & Ireland, Cardiff, 30 June-3 July 2009.

5-**Hany Onsy Habashy**, Desmond G Powe, Graham Ball, Ian O Ellis: Oestrogen Receptor-Positive Breast Cancer: Identification of Significant Prognostic Patho-biological Subgroup. Has been presented as an oral presentation at the 22nd European Congress of Pathology, Florence, Italy, 4-9 September 2009.

6-**Hany Onsy Habashy**, Desmond G Powe, Graham Ball, Enrico Glaab, Daniele Soria, Jonathan Garibaldi, Natalio Krasnogor, Andrew R Green, Carlos Caldas, Ian O Ellis: Luminal-like oestrogen receptor-positive breast cancer: Identification of prognostic biological subclasses. Has been presented as a poster presentation at the 7th European Breast Cancer Conference, Barcelona, Spain, 24-27 March 2010. European Journal of Cancer Suppl. 2010, 8(3):91.

7-**Hany Onsy Habashy**, Desmond G Powe, Graham Ball, Andrew R Green, Emad A Rakha, Ian O Ellis: Oestrogen Receptor Positive Breast Cancer: Prognostic and Biological Significance of Proliferation Assessed by Cyclin B1 and Thymidine Kinase 1 (TK1) Protein Expression. Has been presented as an oral presentation at thescientific meeting of the Pathological Society of Great Britain and Ireland, St. Andrews, 29 June-1 July 2010. Published in the Journal of Pathology, volume 222, Issue S1, Pages S1–S51.

8-**Hany Onsy Habashy**, Desmond G Powe, Graham Ball, Andrew R Green, Emad A Rakha, Ian O Ellis: AGTR1 (Angiotensin II Receptor, Type 1) Expression and Its Prognostic Implications in the ER-Positive Luminal-Like Breast Cancer. Has been presented as an oral presentationat thescientific meeting of the Pathological Society of Great Britain and Ireland,St. Andrews, 29 June-1 July 2010. Published in the Journal of Pathology, volume 222, Issue S1, Pages S1–S51.

9- As invited **speaker, Hany O Habashy**: Fibroepithelial lesions of the breast, 1st Mansoura Nottingham breast cancer symposium, Cairo, 10-11 November 2016.

Selected Scientific Activities

1-The 1st Intensive course of Nephropathology,July 2000, Mansoura University, Mansoura, Egypt.
2-The 15th congress of the International Academy of Pathology (Arab Division),14-16 October 2003, Cairo, Egypt.
3-Intensive course in GastrointestinalPathology,November 2004, Ain Shams University, Cairo, Egypt.
4-Neuropathology course by Professor Bernd W. Scheithaeur,25-27 May 2005, Ain Shams University, Cairo, Egypt.
5-Hematopathology course by Professor Henry Simpkins, 5-6 September 2005, Mansoura University, Mansoura, Egypt.
6- The 10th Nottingham International Breast Cancer Conference,September 2007, Nottingham, UK.
7-The scientific meeting of The Pathological Society of Great Britain and Ireland, 1-4 July 2008,Leeds, UK.
8- The scientific meeting of The Pathological Society of Great Britain and Ireland,30 June-3 July 2009, Cardiff, UK.
9- The 22nd European Congress of Pathology, 4-9 September 2009, Florence, Italy.
10-The 7th European Breast Cancer Conference, 24-27 March 2010, Barcelona, Spain.
11-The scientific meeting of The Pathological Society of Great Britain and Ireland,29 June-1 July 2010, St. Andrews,UK.
12-The 1stBritish Breast Cancer Research Conference,15-17 September 2010, Nottingham, UK.
13-Lung Pathology Course, Kuwait, May 12-16, 2013
14- KCCC/UHN 3rd Annual Pathology Conference, Kuwait, 30th October to 3 rd November 2016
15-1st Mansoura Nottingham breast cancer symposium, Cairo, 10-11 November 2016

16- The 4th annual Pathology conference, Kuwait, November 4-6, 2017

Memberships in Scientific Societies

1-Egyptian Medical Syndicate
2-The Pathological Society of Great Britain and Ireland
3-The European Society of Pathology

Awards

-Award of "Excellence in academic studies" by The Egyptian Embassy in London, UK, 2009.

References

Prof Ian O Ellis

Professor of Cancer Pathology and Honorary Consultant Pathologist
Division of Pathology, School of Molecular Medical Sciences, University of Nottingham
Department of Histopathology, Nottingham City Hospital NHS Trust, Hucknall Road, Nottingham, NG5 1PB, UK
Tel: (0044)115-9691169Fax: (0044)115-9627768
Email: Ian.Ellis@nottingham.ac.uk

Dr Nadia Ibrahim Atwan
Professor of Pathology, Mansoura University, Faculty of Medicine, Egypt
Tel: (0020)1223930470
Email:drnadiaatwan@yahoo.com

Dr Khaled Refaat Zalata
Professor of Pathology and Head of Pathology Department, Mansoura University, Faculty of Medicine, Egypt
Tel: (0020)1005061413
Email:kzalata@yahoo.com

Dr Desmond G Powe

Principle healthcare research scientist
Department Cellular Pathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, UK
Tel: (0044)115-9249924 Ext. 63484
Email: des.powe@talktalk.net